SciSparc Ltd. (SPRC)
| Market Cap | 778.50K -87.4% |
| Revenue (ttm) | 679,000 -61.6% |
| Net Income | -8.22M |
| EPS | -22.11 |
| Shares Out | 580.97K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,468 |
| Open | 1.340 |
| Previous Close | 1.330 |
| Day's Range | 1.310 - 1.362 |
| 52-Week Range | 1.210 - 38.970 |
| Beta | 2.55 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About SPRC
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral ta... [Read more]
Financial Performance
In 2025, SciSparc's revenue was $856,000, a decrease of -34.46% compared to the previous year's $1.31 million. Losses were -$12.18 million, 93.8% more than in 2024.
Financial StatementsNews
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, inc...
SciSparc shifts focus toward Agentic AI-powered technologies
SciSparc (SPRC)announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision ...
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologie...
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
SciSparc (SPRC) announced that NeuroThera Labs highlighted the expansion of the U.S. intellectual property, IP, portfolio through its ongoing collaboration with Clearmind Medicine (CMND). As part of t...
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, su...
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancin...
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancin...
SciSparc subsidiary provides update on SCI-210 trial enrollment
SciSparc (SPRC)announced that NeuroThera Labs continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s SCI-210 treatment for symptoms associated with autism spectr...
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasd...
Neurothera Labs Inc. Announces Share Consolidation
Toronto, Ontario – August 28, 2026 – – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: ...
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
“Psychedelic” is The Fly’s recurring series focused on psychedelic stock news. SCISPARC/CLEARMIND: SciSparc (SPRC) announced earlier this week that its subsidiary, NeuroThera Labs, and Clearmind Medic...
NeuroThera Labs Engages Dr. Reuter Investor Relations
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SP...
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, suc...
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical ...
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million
SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement
T oronto, Ontario – TheNewswire - August 17, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc...
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement
Toronto, Ontario – August 12, 2026 – TheNewswire - NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc L...
SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc...
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
Toronto, Ontario – TheNewswire - A ugust 5 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc ...
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...